Swiss watchdog investigates Novartis over patent use

Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Swiss pharma company reveals SCOTUS appeal plans

22 September 2022 Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Big Pharma

Competition watchdog fines big pharma duo £70m

22 July 2022 The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

Big Pharma

Fed Circuit reverses Novartis’ drug patent win

23 June 2022 The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.

More on this story

Americas

Swiss pharma company reveals SCOTUS appeal plans

22 September 2022 Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Big Pharma

Competition watchdog fines big pharma duo £70m

Big Pharma

Fed Circuit reverses Novartis’ drug patent win

More on this story

Americas

Swiss pharma company reveals SCOTUS appeal plans

22 September 2022 Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Big Pharma

Competition watchdog fines big pharma duo £70m

Big Pharma

Fed Circuit reverses Novartis’ drug patent win